Ridaforolimus Deforolimus MTOR Inhibitors Cas 572924-54-0
Ridaforolimus Deforolimus MTOR Inhibitors cas 572924-54-0
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:Ridaforolimus Deforolimus |
Purity:98% min |
|
CAS NO:572924-54-0 |
Solubility:DMSO≥100 mg/mL (100.98 mM) |
|
Molecular Formula:C53H84NO14P |
Package:Package according to customer requirements |
|
Molecular Weight:990.21 |
Storage:Store at -20℃ |
Quality control
Remarks
Ridaforolimus, also known as AP23573, MK-8669 Deforolimus, is an investigational targeted and small-molecule inhibitor of the protein mTOR, a protein that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival, integrating signals from proteins, such as PI3K, AKT and PTEN known to be important to malignancy. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. It has had promising results in a clinical trial for advanced soft tissue and bone sarcoma.
Related Products
Everolimus; Temsirolimus; PI-103; Torin 1; PF-04691502; Apitolisib; Torin 2; BGT226; Palomid 529; KU-0063794; Rapamycin; Tacrolimus
References
[1].Rivera VM, et al. Deforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011 Jun;10(6):1059-71.
[2].Brandt M, et al. mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects from APC Loss-Dependent Tumorigenesis. Cell Metab. 2018 Jan 9;27(1):118-135.e8.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.